In the Claims

1. (Original) A process of preparing a controlled release oral dosage form comprising:

(a) mixing an active pharmaceutical ingredient and an acrylic polymer to yield a mixture;

(b) forming said mixture into a solid unit dosage form, and

(c) curing said solid unit dosage form.

2. (Original) The process of claim 1, wherein the active pharmaceutical ingredient is selected from the group consisting of morphine, hydromorphone, codeine, oxymorphone, nalbuphine, hydrocodone, dihydrocodeine, dihydromorphine, buprenorphine, oxycodone, naltrexone, naloxone, and pharmaceutically acceptable salts thereof.

3. (Original) The process of claim 1, wherein the acrylic polymer is ammonio methacrylate copolymer.

4. (Original) The process of claim 1, wherein the acrylic polymer comprises of about 10% to about 90% of the weight of said mixture.

5. (Original) The process of claim 4, wherein the acrylic polymer comprises of about 30% to about 70% of the dry weight of said mixture.

6. (Original) The process of claim 1, wherein the step of forming said mixture into a solid unit dosage form comprises dry granulating said active pharmaceutical ingredient with said acrylic polymer.

7. (Original) The process of claim 1, wherein the step of forming said solid unit dosage form comprises compressing said mixture.

8. (Original) The process of claim 1, wherein said solid unit dosage form is a tablet.

9. (Previously Presented) A process of preparing a controlled release oral dosage form comprising:

(a) mixing oxycodone and ammonio methacrylate copolymer to yield a mixture;

(b) forming said mixture into a tablet using dry granulation or direct compression; and

(c) curing said tablet for a time and at a temperature sufficient such that a Differential Scanning Calorimetry (DSC) scan will produce no significant peaks in the region of from about 40° C to about 70° C.

Claims 10 – 15 (Cancelled)

16. (New) The process of claim 1, wherein the active pharmaceutical ingredient is an opioid.